Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) improved overall survival in adults <60 years old with acute myel...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Luskin, Marlise R., Lee, Ju-Whei, Fernandez, Hugo F., Abdel-Wahab, Omar, Bennett, John M., Ketterling, Rhett P., Lazarus, Hillard M., Levine, Ross L., Litzow, Mark R., Paietta, Elisabeth M., Patel, Jay P., Racevskis, Janis, Rowe, Jacob M., Tallman, Martin S., Sun, Zhuoxin, Luger, Selina M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2016
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807422/
https://ncbi.nlm.nih.gov/pubmed/26755712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-07-657403
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller